TTRX: GX-03 phase II interim data show robust efficacy and safety, with stage two now optimized
GX-03 phase II trial for atopic dermatitis advances to an optimized stage two after interim analysis showed strong efficacy and safety, especially in patients with higher pruritus scores. The study uses a stratified, adaptive design and targets a phase II readout in Q4 2026.Based on Turn Therapeuti…